CRNX vs. INSM, HCM, AXSM, PRGO, ALKS, PBH, NUVL, RARE, ALPN, and MDGL
Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Insmed (INSM), HUTCHMED (HCM), Axsome Therapeutics (AXSM), Perrigo (PRGO), Alkermes (ALKS), Prestige Consumer Healthcare (PBH), Nuvalent (NUVL), Ultragenyx Pharmaceutical (RARE), Alpine Immune Sciences (ALPN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.
Crinetics Pharmaceuticals has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Crinetics Pharmaceuticals has higher earnings, but lower revenue than Insmed. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.
Insmed received 367 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 66.83% of users gave Crinetics Pharmaceuticals an outperform vote while only 64.79% of users gave Insmed an outperform vote.
In the previous week, Insmed had 16 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 32 mentions for Insmed and 16 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.66 beat Insmed's score of 0.42 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.
Insmed has a net margin of -236.74% compared to Crinetics Pharmaceuticals' net margin of -4,223.27%. Insmed's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.
Crinetics Pharmaceuticals currently has a consensus price target of $58.42, indicating a potential upside of 13.65%. Insmed has a consensus price target of $44.71, indicating a potential upside of 80.52%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Crinetics Pharmaceuticals.
98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 7.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Insmed beats Crinetics Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Crinetics Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crinetics Pharmaceuticals Competitors List
Related Companies and Tools
